Ischemic Stroke Surgery Companies

Latest Ischemic Stroke Surgery Companies Update

• 
  Jan 2023: Positive results from the TARGET research of the TheraSphere Y-90 Glass Microspheres for individuals with hepatocellular carcinoma (HCC), a prevalent form of primary liver cancer, have been released by Boston Scientific. A form of radioembolization known as TheraSphere comprises millions of tiny glass beads that are radioactively yttrium (Y-90). TheraSphere is the only radioembolization method recommended for treating incurable HCC in the US. Using a dosage technique known as multicompartment dosimetry, the worldwide, retrospective TARGET research examined the safety and effectiveness of TheraSphere therapy in patients with HCC. This reduces the amount of radiation that reaches healthy liver tissue while increasing the amount of Y-90 that reaches the tumor.

• 
  June 2023: Penumbra, Inc., a multinational healthcare organization specializing in cutting-edge treatments, has announced that Lightning BoltTM 7, the most potent and sophisticated artery thrombectomy system available, has received FDA approval and is now available for purchase. With Lightning Bolt 7, a novel approach to removing blood clots is presented: modulated aspiration, which combines a sophisticated microprocessor algorithm with Penumbra's Lightning Intelligent Aspiration technology. When combined, Lightning Bolt 7 is intended to improve the capacity to quickly eliminate big, fibrous blood clots from the arteries and with little blood loss, treating diseases such as visceral occlusions, hibernating thrombus, and acute limb ischemia (ALI).

• Stryker (US)


• Medtronic Plc (Ireland)


• Johnson & Johnson Services Inc. (US)


• Boston Scientific Corporation (US)


• Penumbra, Inc. (US)


• Abbott Laboratories (US)


• Koninklijke Philips N.V. (Netherlands)


• Imperative Care (US)


• Phenox GmbH (Germany)